Aptevo Therapeutics Inc
NASDAQ:APVO

  • LAST PRICE
    0.6800
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    0.6750/ 2
  • Ask / Lots
    0.7000/ 2
  • Open / Previous Close
    0.6875 / 0.6800
  • Day Range
    0.6800
    0.6875
  • 52 Week Range
    0.6700
    90.2000
  • Volume
    4,158

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Apr 15, 2024

      Show headlines and story abstract

    • 4:12PM ET on Monday Apr 15, 2024 by Accesswire
      Companies Mentioned: APVO

      SEATTLE, WA / ACCESSWIRE / April 15, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced the closing of its previously announced public offering of (i) 3,400,000 shares of its common stock or pre-funded warrants in lieu thereof and (ii) warrants to purchase up to an aggregate of 6,800,000 shares of its common stock (the "Common Warrants") at a purchase price of $1.35 per share and associated Common Warrant. Each share of common stock is being offered together with two Common Warrants, each to purchase one share of common stock. The Common Warrants have an exercise price of $1.35 per share, are immediately exercisable for a period of five years following the date of issuance.

    • 4:12PM ET on Monday Apr 15, 2024 by Dow Jones
      Companies Mentioned: APVO

      SEATTLE, WA / ACCESSWIRE / April 15, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR(TM) and ADAPTIR-FLEX(TM) platform technologies, today announced the closing of its previously announced public offering of (i) 3,400,000 shares of its common stock or pre-funded warrants in lieu thereof and (ii) warrants to purchase up to an aggregate of 6,800,000 shares of its common stock (the "Common Warrants") at a purchase price of $1.35 per share and associated Common Warrant. Each share of common stock is being offered together with two Common Warrants, each to purchase one share of common stock. The Common Warrants have an exercise price of $1.35 per share, are immediately exercisable for a period of five years following the date of issuance.

  • Apr 11, 2024

      Show headlines and story abstract

    • 4:11PM ET on Thursday Apr 11, 2024 by MT Newswires
      Companies Mentioned: JNJ, RLYB, APVO
      04:11 PM EDT, 04/11/2024 (MT Newswires) -- US equity markets closed mixed Thursday following the wholesale producer price inflation data for March. * The US producer price index increased 2.1% year-over-year in March, accelerating from 1.6% in Febru...

    • 2:22PM ET on Thursday Apr 11, 2024 by MT Newswires
      Companies Mentioned: GL, NA, APVO
      02:22 PM EDT, 04/11/2024 (MT Newswires) -- Aptevo Therapeutics (APVO) said it priced a public offering of 3.4 million shares and warrants to purchase up to 6.8 million shares at $1.35 a share and associated common warrant, targeting gross proceeds o...

    • 8:01AM ET on Thursday Apr 11, 2024 by Accesswire
      Companies Mentioned: APVO

      SEATTLE, WA / ACCESSWIRE / April 11, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced the pricing of a public offering of (i) 3,400,000 shares of its common stock or pre-funded warrants in lieu thereof and (ii) warrants to purchase up to an aggregate of 6,800,000 shares of its common stock (the "Common Warrants") at a purchase price of $1.35 per share and associated Common Warrant. Each share of common stock is being offered together with two Common Warrants, each to purchase one share of common stock. The Common Warrants will have an exercise price of $1.35 per share, are exercisable upon issuance, and will expire five years following the date of issuance. The offering is expected to close on or about April 15, 2024, subject to customary closing conditions.

Peers Headlines